CFDA Unveils Milestone Plans To Accelerate New Drug Approvals
This article was originally published in PharmAsia News
Executive Summary
A long-awaited China FDA regulatory reform plan covers a range of key areas of focus: narrowing the definition of new drugs, starting marketing authorization holder pilot schemes and widening qualifications for fast-track products. But analysts still see room to improve.